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Doctors around the world are desperately looking for guidance
o enable them to better manage their COVID-19 patients. With no
pecific COVID-19 agents available a range of possible treatment
ptions have been investigated including the use of anti-retroviral
rugs, such as lopinavir/ritonavir, experimental anti-virals such as
emdesivir, and antimicrobial drugs such as chloroquine or hydrox-
chloroquine with or without azithromycin. While some of these
rugs are widely used for other indications, the risk/benefit analy-
is in COVID-19 patients has not thoroughly been evaluated. 
Under normal circumstances, the “holy grail” of evidence is
chieved from well-designed, randomized, controlled trials (RCTs).
owever, in the midst of a pandemic, it is not always possi-
le to provide the “holy grail”. A recent article published in the
MJ suggests there is a widespread issue of compromise of qual-
ty of published or pre-printed papers in response to the pan-
emic [1] . Consequently, in an attempt to enhance the treatment
f patients with COVID-19, the question is asked should health-
are providers, including those responsible for scientific publica-
ions, ignore “lesser evidence” generated from observational stud-
es? In this issue Machiels et al. [2] discuss the scientific merit of
he paper written by Gautret et al. [3] which advocates “COVID-
9 patients be treated with hydroxychloroquine and azithromycin
o cure their infection and to limit the transmission of the virus
o other people.” The publication has received a global and po-
arized response, in part because of its widespread dissemination
y the President of the United States in the form of Tweets, but
ore importantly by a flurry of criticism in the form of social me-
ia activity (approximately 70,0 0 0 mentions) and notification from
olleagues who disputed the study’s design, execution and conclu-
ions. Concerns have been raised on social media regarding the pa-
er’s content, the ethical approval of the study and the process the
anuscript underwent to be published in the International Jour-
al of Antimicrobial Agents (IJAA). As a consequence of the con-
erns raised, the International Society of Antimicrobial Chemother-
py (ISAC) on April 3 and 11, 2020 posted two statements on its
ebsite. The latter statement was made jointly with the journal’s
ublisher, Elsevier [ 4 , 5 ]. In the joint statement we clarified that the
ournal’s standard peer review process was followed in the publi-
ation of this paper. To minimize potential bias, as one of the au-
hors is the Editor in Chief of the journal, the editorial handling
 peer review was delegated to an Associate Editor. Furthermore,
fter publication ISAC arranged an additional independent peer re-DOIs of original articles: 10.1016/j.ijantimicag.2020.106063 , 10.1016/j.ijantimicag. 
020.105949 , 10.1016/j.ijantimicag.2020.106056 
ttps://doi.org/10.1016/j.ijantimicag.2020.106081 
924-8579/© 2020 Published by Elsevier B.V. iew to ascertain whether concerns about the research content of
he paper had merit. 
After internal and external (post-publication) review, some of
he concerns regarding the paper’s methodology were substanti-
ted [6] . Consequently, the ISAC Executive Committee, in collab-
ration with Elsevier, discussed a variety of options in regard to
ow to proceed. Despite the flaws in methodology, we have elected
ot to withdraw the publication by Gautret et al [3] . We believe,
n addition to the importance of sharing observational data at the
eight of a pandemic, a robust public scientific debate about the
aper’s findings in an open and transparent fashion should be
ade available. 
Prior to publication, the authors were invited to respond within
he journal to this editorial and the reviews by Machiels et al.
2] and Rosendaal [6] . At time of publication, a response has been
osted on the authors’ institutional website and is currently under
eview in IJAA. 
ISAC invites researchers to participate in this debate in the form
f Letters to the Editor and wishes to thank the journal’s editor,
ection editors and reviewers for their support, enabling our jour-
als to deliver important knowledge in a timely fashion. 
unding: None. 
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